Bigfoot Biomedical

Bigfoot Biomedical Inc. is a medical technology start-up headquartered in Milpitas, California,[1] founded by a team of people with personal connections to type 1 and type 2 diabetes.[2][3]

On September 22, 2023, Abbott Laboratories announced that it had completed the purchase of the company.[4]

History

The foundation of Bigfoot Biomedical was started when co-founder Bryan Mazlish’s son was diagnosed with type 1 diabetes. Mazlish developed a control algorithm to drive the first automated artificial pancreas device for his wife and son.[5][6]

In 2014, Mazlish joined with Jeffrey Brewer, CEO of Juvenile Diabetes Research Foundation (JDRF), and Lane Desborough, chief engineer at Medtronic, to form SmartLoop Labs in order to scale and commercialize the technology.[6][7]

In February 2015, the company was renamed Bigfoot Biomedical Inc. following an article published in Wired Magazine about the work of Bryan Mazlish as someone who’d successfully hacked their own automated system and dubbing him “Bigfoot.”[8]

In May 2015, Bigfoot acquired the assets of Asante Solutions, former manufacturer of the Snap insulin pump.[9]

In June 2017, Bigfoot acquired London-based start-up Patients Pending, LTD makers of the Timesulin smart insulin pen, to lead the development of a smart pen solution for people utilizing multiple daily injections to manage their diabetes.[10][11]

In July 2017, Bigfoot entered an agreement with Abbott Laboratories to develop and commercialize diabetes management systems integrating Abbott's FreeStyle® Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States.[12]

In July 2020 the FDA accepted for review the Bigfoot Unity™ Diabetes Management Program, a dose-decision support system utilizing proprietary smart pen caps and integrating Abbott’s FreeStyle® Libre 2 continuous glucose monitoring platform.[13]

In September 2023, it was announced Bigfoot had been acquired by the Illinois-headquartered Abbott, for an undisclosed sum.[14]

Portfolio

Bigfoot’s portfolio also includes the Bigfoot Autonomy Diabetes Management Program with a closed-loop, automated insulin delivery system,[15] sometimes referred to as an “artificial pancreas.”[15][16] It received the FDA Breakthrough Device designation.[17][18]

References
  1. "Bigfoot CEO talks data-driven diabetes care and becoming a service company". MedTech Dive. Retrieved 2020-04-17.
  2. Smith, Peter Andrey (22 February 2016). "A Do-It-Yourself Revolution in Diabetes Care". The New York Times. Retrieved 6 April 2016.
  3. Knutson, Ryan (8 June 2015). "Computer Experts Deliver Insulin to Diabetic Kids". The Wall Street Journal. Retrieved 6 April 2016.
  4. "Abbott Completes Acquisition of Bigfoot Biomedical". Abbott Laboratories. Retrieved 2023-10-05.
  5. "No More Sleepless Nights: The Relationship Between Innovative Therapies for Parents of Children with Type 1 Diabetes". Welkin Health. 12 July 2017. Retrieved 11 August 2017.
  6. Hurley, Dan. "Artificial Pancreas Makers Race to Market". Discover Magazine. No. May 2016. Retrieved 6 April 2016.
  7. Evans, Rogene (23 June 2016). "Ones to Watch, ten companies we're keeping an eye on". Medical Design and Outsourcing. Retrieved 28 September 2016.
  8. Hurley, Dan (2014-12-24). "Diabetes Patients Are Hacking Their Way Toward a Bionic Pancreas". Wired. ISSN 1059-1028. Retrieved 2020-09-19.
  9. "Bigfoot Biomedical Ups its Game Through Recent Acquisition and Partnership". Medical Product Outsourcing. 8 June 2015. Retrieved 6 April 2016.
  10. "Bigfoot Biomedical acquires Timesulin". 2017-06-08.
  11. Baum, Stephanie (2017-12-21). "Bigfoot Biomedical closes $37M Series B as it prepares for clinical trials of insulin delivery tech". MedCity News. Retrieved 2019-09-06.
  12. "Abbott, Bigfoot Biomedical collaborate on diabetes technologies". MobiHealthNews. 2017-07-17. Retrieved 2020-09-19.
  13. "Medtronic seeks leg up in lagging pen market with Companion Medical buy". MedTech Dive. Retrieved 2020-09-19.
  14. "Abbott to acquire smart insulin solutions provider Bigfoot Biomedical". NS Medical Devices. 2023-09-06. Retrieved 2023-09-06.
  15. Whooley, Sean (2022-01-27). "How Bigfoot Biomedical plans to take diabetes management forward". Drug Delivery Business. Retrieved 2022-09-21.
  16. Berg, Joel (2020-01-16). "Bigfoot Biomedical lands $45M as it readies first diabetes product". MedCity News. Retrieved 2022-09-21.
  17. "Bigfoot Biomedical for More Accurate Insulin Dosing: Interview with CMO Red Maxwell | Medgadget". 26 March 2020. Retrieved 2020-09-19.
  18. "Bigfoot CEO talks data-driven diabetes care and becoming a service company". MedTech Dive. Retrieved 2020-09-19.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.